Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Deferred Taxes (2019 - 2025)

Vanda Pharmaceuticals' Deferred Taxes history spans 8 years, with the latest figure at $103.2 million for Q4 2025.

  • For Q4 2025, Deferred Taxes rose 5491.12% year-over-year to $103.2 million; the TTM value through Dec 2025 reached $81.4 million, up 1356.45%, while the annual FY2025 figure was $81.4 million, 1356.45% up from the prior year.
  • Deferred Taxes for Q4 2025 was $103.2 million at Vanda Pharmaceuticals, up from -$6.0 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $103.2 million in Q4 2025 and bottomed at -$8.0 million in Q2 2025.
  • The 5-year median for Deferred Taxes is $85500.0 (2022), against an average of $4.1 million.
  • The largest YoY upside for Deferred Taxes was 5491.12% in 2025 against a maximum downside of 3069.51% in 2025.
  • A 5-year view of Deferred Taxes shows it stood at $1.3 million in 2021, then plummeted by 68.24% to $417000.0 in 2022, then plummeted by 1894.72% to -$7.5 million in 2023, then skyrocketed by 74.43% to -$1.9 million in 2024, then soared by 5491.12% to $103.2 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Deferred Taxes are $103.2 million (Q4 2025), -$6.0 million (Q3 2025), and -$8.0 million (Q2 2025).